Seres Therapeutics Inc (NASDAQ:MCRB)‘s stock had its “outperform” rating reaffirmed by stock analysts at FBR & Co in a research report issued on Monday.

A number of other equities research analysts have also commented on MCRB. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Wednesday, February 1st. Cantor Fitzgerald set a $16.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 31st. Canaccord Genuity reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Seres Therapeutics in a research note on Tuesday, January 31st. Finally, Zacks Investment Research raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $23.20.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 1.99% during midday trading on Monday, reaching $11.80. 298,201 shares of the company’s stock traded hands. The company has a 50 day moving average of $9.69 and a 200 day moving average of $10.73. The firm’s market cap is $476.19 million. Seres Therapeutics has a 52-week low of $8.05 and a 52-week high of $35.98.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Thursday, March 16th. The company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.07. The firm earned $3 million during the quarter, compared to the consensus estimate of $3 million. The firm’s quarterly revenue was up NaN% on a year-over-year basis. On average, equities analysts predict that Seres Therapeutics will post ($2.76) EPS for the current fiscal year.

Your IP Address:

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Artal Group S.A. raised its position in shares of Seres Therapeutics by 40.0% in the fourth quarter. Artal Group S.A. now owns 700,000 shares of the company’s stock valued at $6,930,000 after buying an additional 200,000 shares in the last quarter. Ellington Management Group LLC bought a new position in shares of Seres Therapeutics during the fourth quarter valued at about $107,000. Renaissance Technologies LLC raised its position in shares of Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the company’s stock valued at $3,963,000 after buying an additional 103,800 shares in the last quarter. ARK Investment Management LLC bought a new position in shares of Seres Therapeutics during the fourth quarter valued at about $4,871,000. Finally, Trexquant Investment LP raised its position in shares of Seres Therapeutics by 147.5% in the fourth quarter. Trexquant Investment LP now owns 25,924 shares of the company’s stock valued at $257,000 after buying an additional 15,450 shares in the last quarter. 77.62% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

5 Day Chart for NASDAQ:MCRB

Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.